Serplulimab

斯鲁利单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameSerplulimab
Drug Alias Name重组抗PD-1人源化单克隆抗体注射液SlulizumabSolutumabSlulimumab汉斯状 +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursMicrosatellite instability-high cancer +[25] 
Global Approved IndicationsMicrosatellite instability-high cancerSmall Cell Lung Carcinoma
Approved Indications in ChinaMicrosatellite instability-high cancer
Original Approved Country/TerritoryMainland China
Original Approved Date2022/03/22
Country/TerritoryCzechiaUnited StatesUkraine +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFosun Hanlin (Chengdu) Biotechnology Co LtdFosun Hanlin (Shenzhen) Biotechnology Co LtdShanghai Henlius Biologics Co Ltd +[16] 
Inactive CompaniesHenlix Inc
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursMicrosatellite instability-high cancer +[22] 
Inactive IndicationsHead and Neck NeoplasmsNeoplasmsHepatitis B, Chronic

Other Information

ATC CodeL01FF
Related LinksWikipediaDrugBankKEGG